T. Rowe Price Associates, Inc. 13D and 13G filings for Ascendis Pharma A/S:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-16 4:29 pm Sale | 2023-12-31 | 13G | Ascendis Pharma A/S ASND | T. Rowe Price Associates, Inc. | 1,444,950 2.500% | -9,424,610 (-86.71%) | Filing |
| 2024-02-14 10:03 am Purchase | 2023-12-31 | 13G | Ascendis Pharma A/S ASND | T. Rowe Price Associates, Inc. | 10,869,560 2.500% | 7,159,719 (+192.99%) | Filing |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Ascendis Pharma A/S ASND | T. Rowe Price Associates, Inc. | 3,709,841 6.500% | -1,051,352 (-22.08%) | Filing |
| 2022-02-14 2:34 pm Sale | 2021-12-31 | 13G | Ascendis Pharma A/S ASND | T. Rowe Price Associates, Inc. | 4,761,193 8.300% | -1,857,849 (-28.07%) | Filing |
| 2021-02-16 12:23 pm Sale | 2020-12-31 | 13G | Ascendis Pharma A/S ASND | T. Rowe Price Associates, Inc. | 6,619,042 12.300% | -1,142,254 (-14.72%) | Filing |